Carbon Brand Solutions’ Post

#Semaglutide (Ozempic and Wegovy): Uses, Mechanism, and Potential Implications for Contraceptive Effectiveness #Semaglutide (marketed as Ozempic and Wegovy) is a medication primarily used to manage type 2 diabetes. It functions as a GLP-1 receptor agonist, which helps regulate blood sugar levels by stimulating insulin secretion and inhibiting glucagon release. #Recent_Applications_and_Mechanisms_of_Action Recently, semaglutide has garnered attention for its efficacy in promoting weight loss. The drug operates by: - Slowing gastric emptying. - Reducing appetite. - Increasing feelings of fullness. #Clinical_Efficacy Clinical trials have demonstrated that semaglutide can result in significant weight loss for individuals both with and without type 2 diabetes. #Dosage_for_Weight_Loss: The typical starting dose is 0.25 mg once weekly, with a gradual increase to 1 mg once weekly. For weight loss, higher doses, up to 2.4 mg weekly, have been studied. #Interaction_with_Oral_Contraceptives A noteworthy consideration is the potential interaction between semaglutide and oral contraceptives. Recent studies suggest that semaglutide may impact the absorption of oral contraceptives due to its effect on gastric emptying. This delayed gastric emptying may lead to lower plasma concentrations of contraceptives, potentially reducing their effectiveness. There have been reports, particularly among women with PCOS, of pregnancies occurring while using both Ozempic and oral contraceptives. This raises concerns about the reliability of oral contraceptives when used concurrently with semaglutide. #Conclusion If you are considering using Ozempic for weight loss or have concerns regarding its interactions with oral contraceptives, it is essential to consult with your prescribing physician to evaluate the risks and make informed decisions. #Sources: Clinical trials and studies on semaglutide vs weight loss.

CASE STUDY 57 Case Study: Drug Interactions in Preeclampsia A 34-year-old pregnant woman at 30 weeks gestation was diagnosed with preeclampsia after presenting with swelling, headaches, and blurry vision. Her blood pressure was 160/100 mmHg, and proteinuria was detected. Medications Administered Labetalol: 200 mg twice daily for hypertension Magnesium sulfate: IV to prevent seizures Nifedipine: 10 mg PRN for blood pressure control Betamethasone: To promote fetal lung development Drug Interactions Labetalol + Nifedipine: Additive hypotension risk, requiring close blood pressure monitoring. Magnesium Sulfate + Nifedipine: Risk of respiratory depression and muscle weakness due to additive neuromuscular blocking effects. Magnesium Sulfate + Betamethasone: Potential for fluid retention and worsening hypertension. Plan Monitor blood pressure and respiratory function closely. Adjust antihypertensives if hypotension develops. Educate patient on the risks of drug interactions. #pharmacology #medicine #pharma #pharmacy #patient #educate #hypertensives

Wegovy—Novo Nordisk, is now the first weight-loss medication to also win FDA approval as an intervention for lowering cardiovascular (CV) risk in adults with obesity or overweight. The findings showed that Wegovy reduced the risk of stroke, heart attack, and other CV problems by 20% in this population. Semaglutide, which is also the active ingredient in Novo's diabetes drug Ozempic, works by delaying emptying of the stomach — which has the effect of suppressed appetite in users. While FDA's decision raises hope that more insurers will cover Wegovy for more patients, effectively bringing production up to meet demand and driving prices down are still challenges. https://lnkd.in/ePvvr8-H

The FDA has approved Crenessity for managing classic #CAH in patients 4 years and up, reducing steroid doses while controlling hormones, offering a safer treatment option. https://lnkd.in/gKWZKrZH

📍Novo Nordisk diabetes drug Ozempic, known chemically as semaglutide, has shown promising results in a late-stage trial. 📍The drug slowed the worsening of kidney problems and reduced the risk of kidney failure, heart issues, stroke, and death in patients with type 2 diabetes. 📍The trial, which involved weekly 1-milligram injections, found that Ozempic cut the combined risk of these complications by 24% over 3.4 years compared to a placebo. #novonordisk #diabetes #healthmanagement #ozempic #semaglutide #clinicaltrails

Daily Critical Care Pearls #271: "Do Non-Benzo Psychotropic Medications Enhance Respiratory Depression From Opioids? 1. Benzodiazepines and Opioids Risk: Benzodiazepines are known to increase respiratory depression when taken with opioids, prompting the FDA to mandate boxed warnings for both drug classes. 2. FDA's New Focus: The FDA is investigating whether other psychotropic medications, like paroxetine and quetiapine, might have similar interactions with opioids. 3. Study Overview: A preliminary study published in JAMA explored the effects of combining oxycodone with paroxetine or quetiapine on ventilatory response in 25 healthy participants (median age 35). 4. Key Findings: Paroxetine, when combined with oxycodone, significantly reduced ventilatory response to hypercapnia, while quetiapine had no such effect. 5. Study Conclusion: The findings suggest paroxetine-opioid combinations may impair ventilatory response, but further research is needed to confirm long-term and clinical implications. 6. Next Steps: Although this small-scale study won't lead to immediate FDA warnings, it highlights the importance of further investigations into psychotropic-opioid interactions to identify potential respiratory risks. Full study can be accessed through: https://lnkd.in/drm5JCSY #criticalcare #clinicalpharmacy #medicine #pearls

Common diabetes drug may help slow organ aging, monkey study shows Metformin, a drug traditionally used to treat type 2 diabetes, has garnered significant attention for its potential anti-aging effects. Its mechanism involves improving insulin sensitivity, reducing inflammation and promoting cellular repair processes, all important factors in aging. In this new research, experts have discovered that administering the diabetes drug metformin to cynomolgus monkeys can slow aging across multiple organs, including the brain. Cynomolgus monkeys (Macaca fascicularis) are a suitable model for aging studies because, their physiological and functional characteristics resemble those of humans. Metformin may have significant impact on brain All the monkeys experienced a reduction in age-related decline, with some showing brain age indicators resembling those of monkeys six years younger. #drugsafety #diabetes #study #adr #metformin #preclinicaltrials #Fdc #mohf #pharmacovigilance #clinicalresearch #pharma #recentstudy #drugs #medicine

#GLP1's are everywhere. It feels like everyone and their mother is blissfully and religiously injecting themselves with one of these miracle drugs for diabetes or weight loss. But what is actually happening in the real world? It turns out that people don't stay on these drugs despite the sensational results... Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. (Hearn EB, Sherman JJ. Diabetes Spectr. 2021 Jan;34(1):73-75) Can we be curious about why? General injection-site reactions (e.g., erythema, pain, or rash) have been reported with all of the commercially available GLP-1 receptor agonists (i.e., exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) All of them (exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) cause injection site reactions like erythema , pain, rash . How might adherence change if we treated injection site reactions? Imagine what it might feel like for a patient to receive care these these symptoms that we, on the medical side, tend to label as insignificant. What could a Thimble Recover patch do for medication adherence and for the patient experience? Would you want your injections to come with solutions to alleviate the discomfort? #stickwithcompassion